Clinical trial of the week: Study of patients scheduled to undergo TAVR

By Donna Loyle, communications specialist, LIMR


Researchers seek to determine if use of the FDA-approved Sentinel® Cerebral Protection System significantly reduces the risk of stroke in patients undergoing a transcatheter aortic valve replacement (TAVR). The Sentinel System captures and removes embolic material during a TAVR and is meant to reduce ischemic injury to the brain.


Eligible participants in the post-market, multicenter Protected TAVR clinical study are those with aortic valve stenosis and in need of a TAVR. Subjects to be treated via a transfemoral approach will be randomized 1:1 into either the Test cohort (TAVR using the Sentinel) or the Control cohort (TAVR without using the Sentinel).


The study is approved for Lankenau Medical Center. The principal investigator is Roberto Rodriguez, MD. For more, visit

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *